Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kun Yu

Showing results (1001-1010 of 1,009) with videos related to

Pageof 101
Sort By:
You have reached the last page of results.This site can display upto 1,009 results.
Lancet (London, England)|June 10, 2021
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialYu-Pei Chen, Xu Liu, Qin Zhou, et al.
Nature Cancer|July 1, 2026
Long-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 studyYa-Lan Tao, Dong-Hong Wu, Qin Zhou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2022
Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III TrialYuan Zhang, Lei Chen, Guo-Qing Hu, et al.
The New England Journal of Medicine|June 1, 2019
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal CarcinomaYuan Zhang, Lei Chen, Guo-Qing Hu, et al.
The Lancet. Oncology|September 4, 2025
Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlasLing-Long Tang, Cheng-Long Huang, Shao-Jun Lin, et al.
The Lancet. Oncology|September 4, 2025
Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlasLing-Long Tang, Cheng-Long Huang, Shao-Jun Lin, et al.
Lancet (London, England)|June 2, 2024
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialXu Liu, Yuan Zhang, Kun-Yu Yang, et al.
JAMA|March 13, 2025
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical TrialYe-Lin Liang, Xu Liu, Liang-Fang Shen, et al.
JAMA|August 21, 2025
Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial, Cheng Xu, Xiao-Yu Liang, et al.
Pageof 101

Showing results (1001-1010 of 1,009) with videos related to

Sort By:
Pageof 101
You have reached the last page of results.This site can display upto 1,009 results.
Lancet (London, England)|June 10, 2021
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialYu-Pei Chen, Xu Liu, Qin Zhou, et al.
Nature Cancer|July 1, 2026
Long-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 studyYa-Lan Tao, Dong-Hong Wu, Qin Zhou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2022
Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III TrialYuan Zhang, Lei Chen, Guo-Qing Hu, et al.
The New England Journal of Medicine|June 1, 2019
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal CarcinomaYuan Zhang, Lei Chen, Guo-Qing Hu, et al.
The Lancet. Oncology|September 4, 2025
Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlasLing-Long Tang, Cheng-Long Huang, Shao-Jun Lin, et al.
The Lancet. Oncology|September 4, 2025
Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlasLing-Long Tang, Cheng-Long Huang, Shao-Jun Lin, et al.
Lancet (London, England)|June 2, 2024
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialXu Liu, Yuan Zhang, Kun-Yu Yang, et al.
JAMA|March 13, 2025
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical TrialYe-Lin Liang, Xu Liu, Liang-Fang Shen, et al.
JAMA|August 21, 2025
Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial, Cheng Xu, Xiao-Yu Liang, et al.
Pageof 101